North Carolina, USA-based TARGET PharmaSolutions has entered into a strategic partnership with Gilead Sciences for TARGET-NASH and TARGET-HBV. 20 November 2018
MorphoSys and I-Mab Biopharma have entered into an exclusive strategic collaboration and regional licensing agreement for MOR210, a candidate which the firms believe has the potential to be developed as an immuno-oncology agent. 16 November 2018
Belgian biotech Convert Pharmaceuticals has appointed Mariola Söhngen as chief executive. The Liège-based firm is gearing up for clinical testing of its lead oncology candidate. 9 November 2018
Oxford BioDynamics has entered into its fifth collaboration agreement for the development of predictive biomarkers for immuno-oncology (IO) therapeutics. 8 November 2018
UK-incorporated Mallinckrodt has missed the primary endpoint of a Phase IIb/III study of VTS-270 for the treatment of Niemann-Pick Type C, a rare genetic condition. 8 November 2018
Belgian ophthalmology specialist Oxurion has entered into a strategic research collaboration with Australian company Beta Therapeutics to develop new heparanase inhibitors for the treatment of retinal disorders with large unmet medical needs such as dry age-related macular degeneration (AMD). 6 November 2018
Bristol-Myers Squibb and Infinity Pharmaceuticals have entered into a clinical trial collaboration to evaluate B-MS’s blockbuster drug Opdivo (nivolumab) in combination with Infinity's IPI-549 in patients with advanced urothelial cancer. 5 November 2018
Dutch company ProQR Therapeutics has announced the signing of an agreement with Ionis Pharmaceuticals to license QR-1123, an RNA medicine for autosomal dominant retinitis pigmentosa (adRP) caused by the P23H mutation in the rhodopsin gene. 29 October 2018
ASX and Nasdaq listed biotech firm Kazia Therapeutics has added two further indications to the development program for its brain-penetrant PI3K inhibitor GDC-0084 through collaborations with prestigious US-based cancer centers. 29 October 2018
The European Commission (EC) has approved a label update for Cosentyx (secukinumab), says the drug’s marketer, Swiss Pharma giant Novartis. 26 October 2018
Parisian biotech Deinove and a non-profit drug discovery group Calibr are to collaborate to explore the anti-infectious potential of the French firm’s bacterial collection. 25 October 2018
The US Institute for Clinical and Economic Review (ICER) yesterday announced that it will not proceed with its comparative clinical effectiveness and value assessment of canakinumab. 25 October 2018
Chinese biopharma BeiGene has announced the acceptance by the China National Medical Products Administration (NMPA) of a new drug application (NDA) for zanubrutinib, an investigational Bruton's tyrosine kinase inhibitor, for relapsed/refractory (R/R) chronic lymphocytic leukemia or small lymphocytic lymphoma. 24 October 2018
Swiss drug developer Idorsia today announced that a representative of former Axovan shareholders claims the demerger of Actelion and Idorsia would trigger the acceleration of all outstanding milestone payments for clazosentan and has filed a complaint with the arbitrator in Switzerland against Actelion. 24 October 2018
Bristol-Myers Squibb has presented results showing Opdivo (nivolumab) plus low-dose Yervoy (ipilimumab) achieved a 60% objective response rate in certain patients with previously untreated metastatic colorectal cancer. 23 October 2018
US drugmaker AbbVie today announced global resolution of all intellectual property-related litigation with Fresenius Kabi over its proposed biosimilar adalimumab product. 18 October 2018
Italian pharma major Recordati saw its shares rise more than 5% to 52.00 euros in early trading, as it announced a deal to expand its portfolio of marketed rare disease medicines. 4 October 2024
Paris-based asset manager Kurma Partners has raised 140 million euros ($154 million), successfully completing the first closing of Biofund IV 4 October 2024
Bristol Myers Squibb has received a new approval from the US Food and Drug Administration for its blockbuster checkpoint blocker, Opdivo (nivolumab). 4 October 2024
Singapore’s Agency for Science, Technology and Research (A*STAR) and US biotech incubator Flagship Pioneering have agree to collaborate on advancing health and sustainability outcomes in Singapore and the broader Asia Pacific region. 4 October 2024
The US Food and Drug Administration (FDA) has removed the partial clinical hold on delpacibart etedesiran (del-desiran/AOC 1001), an investigational treatment designed to address the root cause of myotonic dystrophy type 1 (DM1), under development by US biotech Avidity Biosciences . 4 October 2024
The US Food and Drug Administration (FDA) has granted the Gilead Sciences subsidiary Kite a Regenerative Medicine Advanced Therapy Designation (RMAT) for Yescarta (axicabtagene ciloleucel) for adults with newly-diagnosed, high-risk large B-cell lymphoma (LBCL). 3 October 2024
Kedrion Biopharma has finalized an agreement with Germany-based Biotest for the long-term commercialization and distribution of Yimmugo (immune globulin) in the USA. 3 October 2024
US clinical-stage biotech Arcus Biosciences has entered into a clinical trial collaboration with AstraZeneca on renal cancer treatments. 3 October 2024
PeptiDream says that its wholly-owned PDRadiopharma subsidiary has entered into a strategic partnership with French nuclear medicines firm Curium. 3 October 2024
Privately-held Ferring Pharmaceuticals has announced the opening of a global manufacturing hub in Finland for the drug substance of its intravesical non-replicating gene therapy Adstiladrin (nadofaragene firadenovec-vncg). 3 October 2024
Shares of UK drug developer Hemogenyx Pharmaceuticals rose as much as 9% and closed up 5.9% at 1.70 pence yesterday on the news of a further investment from Prevail Partners. 3 October 2024
UK-based biotech Resolution Therapeutics has announced the completion of a £63.5 million ($76.8 million) series B financing round led by Syncona. 3 October 2024
The BioIndustry Association (BIA), in collaboration with the Centre for Process Innovation (CPI), has published a new report on the UK’s mRNA sector. 2 October 2024
Aspen Neuroscience, a private biotechnology company specializing in autologous cell therapies, has announced the opening of a major new facility near its headquarters in San Diego. 2 October 2024
Privately-held UK biotech Curve Therapeutics today announced the further strengthening of its leadership team with the appointments of Andre Hoekema as chairman of the board and Cora Griffin as head of business development. 2 October 2024